MCROBERTS BV

Their core work

McRoberts develops wearable sensor systems and the underlying algorithms that turn raw movement data into clinically meaningful measurements — capturing how patients actually move in the real world, not just in a lab. Their core product line (MoveMonitor, DynaPort) records continuous physical activity data over days or weeks, which clinical research teams then use to assess disease progression, treatment response, and functional decline. In H2020, they contributed this measurement infrastructure to two large clinical consortia studying conditions ranging from Parkinson's disease and COPD to immune-mediated inflammatory disorders, validating their sensors as regulatory-grade digital endpoints. Their value in a consortium is concrete: they provide the hardware, the signal-processing expertise, and the clinical data pipeline that turns a wearable into an accepted outcome measure.

What they specialise in

How they've shifted over time

Both H2020 projects started in 2019, so the chronological spread is narrow — but the thematic shift between them is meaningful. MOBILISE-D anchored McRoberts in classical mobility science: walking speed, gait quality, and physical activity in well-defined populations like COPD patients, Parkinson's patients, and hip fracture survivors. IDEA-FAST then pushed the platform into less charted territory — immune-mediated inflammatory disorders, fatigue, sleep, and health-related quality of life — conditions where measurement is harder and clinical consensus on what to measure is still forming. This suggests McRoberts is deliberately expanding from established mobility endpoints toward a broader digital outcomes platform capable of capturing the full spectrum of how chronic disease affects daily life.

McRoberts is moving from single-domain mobility measurement toward a multi-outcome digital health platform that covers movement, fatigue, sleep, and quality of life — making them increasingly relevant to any clinical trial or observational study that needs real-world patient monitoring across complex chronic conditions.

How they like to work

McRoberts operates exclusively as a participant, not a coordinator — they join large consortia as a specialist technology provider rather than driving the research agenda themselves. Both their projects are major RIA consortia (MOBILISE-D spans 2019–2024 and IDEA-FAST runs to 2026), suggesting they are comfortable sustaining long-term, multi-year measurement commitments within complex multi-partner structures. With 86 unique partners across 17 countries from just two projects, they have broad network exposure, but this is a function of the large consortia they joined rather than evidence of a dense bilateral partner network.

McRoberts has reached 86 unique consortium partners across 17 countries through just two projects — a reflection of the scale of MOBILISE-D and IDEA-FAST, both large pan-European clinical research consortia. Their network spans primarily European academic medical centres, hospitals, and digital health SMEs, with The Hague as their base and no apparent geographic concentration beyond EU health research hubs.

What sets them apart

McRoberts occupies a narrow but high-value niche: they are one of the few European SMEs that combine proprietary wearable hardware with validated clinical-grade algorithms, giving them credibility in both the engineering and the regulatory science communities. Most digital health SMEs either build devices or consult on endpoints — McRoberts does both, and their participation in MOBILISE-D (which has an explicit regulatory endorsement goal) means their measurement methods are being stress-tested against EMA and FDA standards. For a consortium that needs a wearable partner who can defend their data in a regulatory submission, that track record is difficult to replicate from scratch.

Highlights from their portfolio

• MOBILISE-D
  The largest of their two projects (€519K to McRoberts alone) and one of the most ambitious digital health initiatives in H2020, explicitly targeting regulatory endorsement of digital mobility endpoints — a rare goal that puts McRoberts' sensor data directly in front of medicines regulators.
• IDEA-FAST
  Extends McRoberts' platform into immune-mediated inflammatory disorders and fatigue/sleep monitoring through 2026, demonstrating that their wearable technology is being adopted beyond the neurological disease niche where they first built their reputation.